 
    
 
 
 
Pivotal Study of the MicroVention, Inc. Flow Re -Direction Endoluminal Device (FRED) 
Stent System in the Treatment of Intracranial Aneurysms  
 
NCT 01801007 
Document Date: July 13, 2018 
 
  
CONF
IDENTIAL  Page 1 of 21  STATISTI CAL ANALYSIS P LAN 
Protocol Title ( Number): 
Pivotal Study of the MicroVenti on, Inc. Flow  Re-Direction Endoluminal Device Stent  System in 
the Treatment of  Intracranial A neurysms 
Study Number: CL12001 
Regulatory Agency: FDA 
IDE Number: G120111 
Protocol  Date: 
November 14, 2016 
SAP Ve rsion:  
Version 2 
SAP D ate: 
July 13, 2018 
CONFIDENTIAL 
 
 
 
 CONFIDENTIAL  Page 3 of 21  
  Table of  Contents  
1 Summary  .................................................................................................................................. 5 
2 Prospective Study Overview  ................................................................................................... 7 
2.1 Study Assessments  ........................................................................................................... 8 
3 Study Objectives and Endpoints  .............................................................................................. 8 
3.1 Study Objective  ................................................................................................................ 9 
3.2 Primary Endpoints  ............................................................................................................ 9 
3.3 Study Success  ................................................................................................................... 9 
3.4 Secondary Endpoints  ........................................................................................................ 9 
4 Planned Analyses  ................................................................................................................... 10 
4.1 Analyses and Reporting ................................................................................................. 10 
4.2 Interim Analyses  ............................................................................................................ 11 
4.3 Final Analyses  ................................................................................................................ 11 
5 Analysis Populations  ............................................................................................................. 12 
6 General Considerations  .......................................................................................................... 12 
6.1 Baseline  .......................................................................................................................... 12 
6.2 Criteria for Success For Primary Endpoint Analyses ..................................................... 12 
6.3 Analysis Software  .......................................................................................................... 13 
6.4 Disposition of Subjects and Withdrawals  ...................................................................... 13 
6.5 Protocol Deviations  ........................................................................................................ 13 
6.6 Missing Data Imputations  .............................................................................................. 14 
6.7 Multiple Comparisons and Multiplicity  ......................................................................... 14 
7 Endpoint Analyses  ................................................................................................................. 14 
7.1 Primary Efficacy Variable  .............................................................................................. 14 
7.2 Primary Safety Endpoint  ................................................................................................ 15 
7.3 Missing Data Analyses  ................................................................................................... 16 
7.4 Center Heterogeneity ...................................................................................................... 17 
7.5 Subgroup Analysis  ......................................................................................................... 18 
7.6 Secondary Endpoint Variables  ....................................................................................... 18 
7.6.1  Protocol Defined Secondary Endpoint Variables  ................................................... 19 
 
 
 
 CONFIDENTIAL  Page 4 of 21  
  7.7 Medical History  .............................................................................................................. 19 
7.8 Labs  ................................................................................................................................ 19 
7.9 Procedure  ........................................................................................................................ 19 
8 Adverse Events  ...................................................................................................................... 20 
8.1 All Adverse Events ......................................................................................................... 20 
8.2 Serious Adverse Events  .................................................................................................. 20 
8.3 Deaths  ............................................................................................................................. 20 
9 Other Planned Analyses ......................................................................................................... 21 
9.1 Concomitant Medications  .............................................................................................. 21 
9.2 Device Observations  ...................................................................................................... 21 
9.3 Additional Interventions and Reinterventions ................................................................ 21 
9.4 Statistical Analysis Plan Revisions  ................................................................................ 21 
 
  
 
 
 
 CONFIDENTIAL  Page 5 of 21  
  Abbreviations  
Table of Abbreviations  
Abbreviation  Definition  
AE Adverse Event  
CEC  Clinical Events Committee  
CRF  Case Report Form  
CSR  Clinical Study Report  
CT Computerized Tomography  
DSMB  Data Safety & Monitoring Board  
FDA  United States Food and Drug Administration  
ITT Intent -To-Treat Population  
IA Intracranial Aneur ysm 
FRED  Trial Name from protocol  
mRS  Modified Rankin Scale  
NIHSS  NIH Stroke Scale  
OPC  Objective Performance Criterion  
OUS  Outside of United States  
PP Per-Protocol Population  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
US United States  
 
 
1 SUMMARY  
Title  Pivotal Study of the MicroVention, Inc. Flow Re -Direction Endoluminal Device Stent 
System in the Treatment of Intracranial Aneurysms  
Preface  This Statistical Analysis Plan (SAP) describes the planned analysis and reporting  for 
protocol CL12001  (Pivotal Study of the MicroVention, Inc. Flow Re -Direction 
Endoluminal Device Stent System in the Treatment of Intracranial Aneurysms .). This 
study is being completed to assess th e safety and effectiveness  of the FRED  for the 
treatment of intracranial aneurysms . 
The following documents were reviewe d in preparation of this SAP:  
â€¢ Clinical Research Protocol CL1 2001 rev 4, issued September  27, 2016 
 
 
 
 CONFIDENTIAL  Page 6 of 21  
  â€¢ Annotated eCRF Live v1.0  dated 19Apr2016  
â€¢ FDA Presubmission Q140977  
Purpose  The purpose of this SAP is to prospectively outline the planned analyses to be completed 
to support the completion of the Clinical Study Report (CSR) for protocol CL1 2001. The 
planned analyses identified in this  SAP will be included in  regulatory submissions and 
future manuscripts. Any post-hoc, exploratory analyses completed to support planned 
study analyses, which were not identified in this SAP, will be documented and reported 
in appendices to the CSR.  
Device  Name And 
Intended Use  The device  is called FRED  (Flow Re -Direction Endolu minal Device ) is indicated for the 
endovascular treatment of adults harboring intracranial aneurysms with a high likelihood 
for failure or recurrence with conventional techniques  including wide -necked or 
geometrically complex intracranial aneurysms (including fusiform aneurysms) in the 
anterior and posterior cerebral circulation . 
Primary Endpoints  The primary effectiveness  endpoint is successful aneurysm treatment with the FRED  
Device as defined by complete occlusion utilizing the Raymond scale of the target 
aneurysm  and â‰¤50% stenosis of the parent artery at the tar get IA at 12 months as 
assessed by angiography and in whom an alternate treatment of the target IA has not 
been perfor med within  12 months  post-FRED Device placement . 
The primary safety  endpoint is death or major stroke within 30 days  post procedure , or 
neurological death or major ipsi lateral stroke within 12 months  post-procedure.  
Secondary 
Endpoints  Secondary e ndpoints  described in the protocol are listed below:  
1) Proportion of subjects with clinically acceptable (90 -100%) occlusion of the 
target aneurysm, â‰¤ 50% stenosis of the parent artery at the target IA at 12 
months (+ 60 days, - 30 days). as assessed by angiography, and in whom an 
unplanned alternative treatment of the target IA had not been performed within 
12 months  
2) Proportion of subjects in whom an unplanned alternative treatment of the target 
IA had not been performed within 12 months    
3) Proportions of subjects with clinically acceptable aneurysm occlusion (90 % -
100 %) of the target aneurysm at 12 months (+ 60 days, - 30 days).   
4) Incidence of â‰¥ 50% In -Stent Stenosis (ISS) at the target IA at 12 months as 
assessed by angiography at an independent corelab   
5) Proportion of subjects with complete occlusion of the target aneurysm on 12 -
month angiography (+ 60 days, - 30 days).  
6) Incidence of FRED System procedure related Serious Adverse Events  
7) Incidence of FRED System device -related Serious Adverse Events;  
8) Incidence of unsuccessful delivery of the FRED system implant;  
9) Incidence of unsuccessful deployment of the FRED flow -diverter intra -cranial 
stent  
10) Incidence of migration of the FRED system implant at 12 months;  
11) Unplanned alternative treatment on  the target IA within 12 months, defined as 
re-treatment of the target aneurysm with an alternative treatment modality 
including open repair, endovascular placement of an additional stent or 
treatment of In -stent Stenosis observed at the 180 day or 12 mont h follow -up 
time-points or at an unscheduled study follow up visit.   
12) Change in clinical and functional outcomes at 180 days and 1 year follow up, as 
measured by an increase in the modified Rankin Scale compared to baseline;  
13) Incidence of major stroke, as measured by NIHSS at 12 months (and 
ophthalmic examination related to the target aneurysm if determined 
appropriate.  
 
 
 
 CONFIDENTIAL  Page 7 of 21  
  14) Incidence of minor stroke, as measured by NIHSS at 12 months (and 
ophthalmic examination related to the target aneurysm if determined 
appro priate. . 
Study Design  A multi -center, prospective, single -arm stud y with follow -up at discharge, 30 days (Â± 7 
days), 180 days (Â± 30 days) and 12 months ( + 60 days, -30 days ).  Data will be analyzed 
according to nominal visit, e.g . 30 days, 180 days, 12 months as opposed to actual date.  
The intent -to-treat (ITT) population as defined below will be the primary population for 
all efficacy analyses and the safety population for all safety analyses. One hundred forty -
five (145)  subjects  will constitute the ITT  cohort, which is identical to the Safety cohort.  
These subjects were enrolled and treated at 23 sites located in United States and Japan . 
Subjects are included in study analyses consistent with the prospective literature control, 
with efficacy and safety obj ective performance criteria ( OPCs) used to determine sample 
size.   
Two OPC sets will be considered in support of efficacy and safety as per the original 
protocol (primary) as well as more strict (supportive)  OPCs as follows:  
â€¢ Primary: Original PG specified in the protocol (45% for efficacy and 25% for safety)  
â€¢ Supportive: Updated PG presented to FDA at the  Feb 2017 meeting (46% for 
efficacy and 15% for Safety) .  
Study success is defined as achievin g statistical significance for the primary OPCs.  
 
Primary Analyses:  The po wers will be 80% to rule out a 45% OPC  (efficacy)  margin  
(lower bound)  and 80% to rule out a 25% OPC (safety) margin  (upper bound)  using one -
sided tests .  The trial will be considered successful if the one -sided 95% credible lower 
bound of the efficacy rate exceeds the 45% OPC and the one -sided 95% credible upper 
bound of the safety rate is below the 25% OPC.   The use of one -sided testing is 
consistent with the protocol.  
Supportive Analyses: The powers will be 90% to rule out a 4 6% OPC (efficacy) margin 
(lower bound)  and 90% to rule out a 1 5% OPC (safety) margin (upper bound) using tw o-
sided tests.  The trial will be considered successful if the tw o-sided 95% credible lower 
bound of the efficacy rate exceeds the 46 % OPC and the tw o-sided 95% credible upper 
bound of th e safety rate is below the 1 5% OPC.   The use of two -sided testing is 
consistent with the PIPELINE PMA and FDA guidance.  
Follow -Up Schedule  All enrolled and treated subjects had follow up scheduled at  30 day ( Â± 7 days), 180 days 
(Â± 30 days), and  12 months ( + 60 days, - 30 days ). 
 
Interim Analyses  No interim analysis are planned.  
Final Analyses  This SAP covers analyses planned for the FRED trial, designed to investigate the saf ety 
and eff icacy  of the FRED  during the course of treatment and through 12 months  
following treatment.  
All analyses identified in this SAP relat e to subject data up to and including the 12 -
month follow -up visit. Any post -hoc, or unplanned, analyses not identified in this SAP 
will be clearly  identified in the CSR . 
 
2 PROSPECTIVE STUDY OVERVIEW  
 
 
 
 CONFIDENTIAL  Page 8 of 21  
  FRED  is a single -arm pivotal study in the treatment of  intracranial aneurysms in which subjects 
will be implanted with FRED .  Current common therapies, such as surgical or endovascular 
approach es, are not able to treat intracranial aneurysms with wide necks  effectively . Currently in 
the US, there is one flow diverter, the Pipeline Embolization Device (PED) , approved by FDA 
and there are currently three CE Mark approval s for Pipeline, SIL K and the NeuroEndoGraft. 
Subjects enrolled into the study and treated with FRED  shall be followed at discharge and 30 
days, 180 days  and 12 months . A subject considered enrolled but not treated because of a failed 
FRED  deployment  because of issues related  to the procedure  shall be closely monitored for one 
(1) week.  If the device entered the blood stream and the subject has an Adverse Event, that 
subject will have the 30- day, 180 days  and 12- month clinical follow -ups. If the FRED Device 
enters the blood st ream and cannot be deployed secondary to technical issues with the device 
itself (e.g., FRED Device malfunction or failure to  access the target site due to the FRED 
Device), the Subject will be counted as enrolled with intent -to-treat. This will be conside red as a 
secondary endpoint failure. The Subject will be maintained within the study and will not be 
replaced by another Subject. If the FRED device never entered the subjectâ€™s bloodstream that 
subject will be excluded from all the analysis populations.  No additional analysis is planned for 
data collected beyond 12 months study follow up period. 
 
This study incorporates the use of an independent blinded Clinical Events Committee (CEC)  
which reviewed and adjudicated all the primary and secondary safety out come measures of the 
study , as well as all the adverse events and technical events reported in the study.  In addition, 
independent blinded Data Safety and Monitoring Board which provided study safety and efficacy 
oversight reviewed all the site -reported an d CEC adjudicated clinical data of the FRED study , 
and an independent angiographic core lab oratory  determined aneurysm occlusion and the degree 
of device stenosis reported by the investigational sites. 
2.1 STUDY ASSESSMENTS  
All s ubjects enrolled into the study  and treated with the FRED  shall be followed as stated in the 
study protocol, at discharge and 30 day s (Â± 7 days), 180 days  (Â± 30 days ), and 12 months  (+60 
days, -30 days ): 
1. Discharge interval  shall include a clinical and neurological evaluation  
2. 30-day foll ow-up shall include a clinical and neurological evaluation  
3. 6-month follow -up shall include a clinical, neurological and angiographic evaluation  
4. 12-month follow -up shall include a clinical, neurological and angiographic evaluation  
3 STUDY OBJECTIVES AND ENDPO INTS  
 
 
 
 CONFIDENTIAL  Page 9 of 21  
  3.1 STUDY OBJECTIVE  
The objective of this study is to  evaluate the safety and effectiveness of the MicroVention FRED 
System when used in the treatment of wide -necked intracranial aneurysms.  
3.2 PRIMARY ENDPOINTS  
Primary Safety Endpoint:  
The primary safety endpoint is the proportion of subjects who experience one or more of the 
following:   
a. death or major stroke within 30 days post procedure   
b. neurological death or major ipsilateral stroke within 12 months post procedure  
  
ï‚ª A major stroke is defined as a new neurological event that persists for > 24 
hours and results in a >  4-point increase in the NIHSS score compared to 
baseline or compared to any subsequent lower score.  
ï‚ª A major ipsilateral stroke is defined as that occurri ng within the vascular 
distribution of the stented artery   
ï‚ª Neurologic death is defined as a death which has been adjudicated by the 
independent clinical events committee to have directly resulted from a 
neurologic cause   
  
Primary Effectiveness  Endpoint :  
Proportion of subjects with complete occlusion  of the target aneurysm  utilizing the Raymond 
Scale and â‰¤ 50% stenosis of the parent artery at the target IA at 12 months as assessed by 
angiography and in whom an alternative treatment of the target IA had no t been performed 
within 12 months  post -FRED placement ; where an  alternative treatment is defined as re -
treatment of the target aneurysm with an alternative treatment modality including open repair, 
endovascular placement of an additional stent or treatment  of In -stent Stenosis observed at the 
180 day or 12 month follow -up time -points or at an unscheduled study follow up visit. 
3.3 STUDY SUCCESS  
Study success is defined as establishing the one -sided 95% credible bounds  (primary) for both 
the safety and efficacy endpoints according to the respective OPCs.  
3.4 SECONDARY  ENDPOINTS  
Secondary e ndpoints described in the protocol are listed below:  
1. Proportion of subjects with clinically acceptable (90- 100%) occlusion of the target 
aneurysm, â‰¤ 50% stenosis of the parent artery at the target IA at 12 months (+ 60 days, -
30 days). as assessed by angiography, and in whom an unplanned alternative treatment of 
the target IA had not been performed within 12 months  
 
 
 
 CONFIDENTIAL  Page 10 of 21  
  2. Proportion of subjects in whom an unplanned alternative treatment of the target IA had 
not been performed within 12 months    
3. Proportions of subjects with clinically acceptable aneurysm occlusion (90 % -100 %) of 
the target aneurysm at 12 months (+ 60 days, - 30 days).   
4. Incidence of â‰¥  50% In -Stent Stenosis  (ISS)  at the target IA at 12 months as assessed by 
angiography at an independent corelab   
5. Proportion of subjects with complete occlusion of the target aneurysm on 12 -month 
angiography (+ 60 days, -30 days).  
6. Incidence of FRED System procedure related Serious Adverse Events  
7. Incidence of FRED System device- related Serious Adverse Events;  
8. Incidence of unsuccessful delivery of the FRED system implan t;  
9. Incidence of unsuccessful deployment of the FRED flow -diverter intra -cranial stent  
10. Incidence of migration of the FRED system implant at 12 months;  
11. Unplanned alternative treatment on the target IA within 12 months, defined as re -
treatment of the target aneurysm with an alternative treatment modality including open 
repair, endovascular placement of an additional stent or treatment of In- stent Stenosis 
observed at the 180 day or 12 month follow -up time -points or at an unscheduled study 
follow up visit.   
12. Change in clinical and functional outcomes at 180 days and 1 year follow up, as 
measured by an increase in the modified Rankin Scale compared to baseline;  
13. Incidence of major stroke, as measured by NIHSS at 12 months (and ophthalmic 
examination related to the target aneurysm if determined appropriate.  
14. Incidence of minor stroke, as measured by NIHSS at 12 months (and ophthalmic 
examination related to the target aneurysm if determined appropriate.  
4 PLANNED ANALYSES  
4.1 ANALYSES AND REPORTING  
Study analyses for primary efficacy and safety endpoints will be conducted using Bayes ian 
methods, consistent  with other medical device submissions to CDRH  to allow the computation of 
credible limits for assessment of the statistical hypotheses .  This decision was made in advance 
of any data assessments for either efficacy or safety.  Other outcomes, including secondary 
endpoints for which formal hypothesis testing is not prespecified, will be presented descriptively 
with Bayesian credible intervals  to correspond to the prima ry or supportive analyses . 
All analyses identified in this SAP relate  to primary, secondary, and exploratory endpoints 
focused at time points , 30 days, 180 days, and up to and including 12 months . Key statistics and 
study results will be made available to the Project Team following database lock and prior to 
completion of the final CSR .  Any post -hoc, exploratory analyses completed to support planned 
study analyses,  which were not identified in this SAP, will be documented and reported in 
 
 
 
 CONFIDENTIAL  Page 11 of 21  
  appendices to the CSR. Any results from these unplanned analyses will also be clearly identified 
as post hoc in the text of the CSR.  
Safety data will be review ed and adjudication of all adverse events reported in the study will be 
performed by an independent  blinded Clinica l Events Committee  (CEC ); the CEC will also 
review all protocol deviations . Safety will be based on the CEC findings.  In addition, a Data 
Safety and Monitoring Board (DSMB) will review all site -reported and CEC -adjudicated clinical 
data.  These safety rev iews will be conducted only for the benefit of members of the DSMB  in 
accordance with the DSMB  charter .  Because these interim safety reviews will not include 
inference procedures (confidence intervals or hypothesis tests), and because these safety  analyses 
reviews will not be shared outside the DSMB , no alpha spending adjustment s are required for the  
final analyses.   
4.2 INTERIM ANALYSES  
No interim analys es are planned . 
4.3 FINAL ANALYSES  
Final statistical analyses will be performed as detailed below.  
Two OPC sets will be considered in support of efficacy and safety as per the original protocol as 
well as more restrictive  OPCs as follows:  
â€¢ Primary: Original PG specified in the protocol (45% for efficacy and 25% for safety)  
â€¢ Supportive: Updated PG presente d to FDA at the Feb 2017 meeting (46% for efficacy  
and 15% for Safety).  
Primary Analyses:  The powers w ill be 80% to rule out a 45% OPC (efficacy) margin (lower 
bound) and 80% to rule out a 25% OPC (safety) margin (upper bound) using one -sided tests.  
The trial will be considered successful if the one -sided 95% credible lower bound of the efficacy 
rate exceeds the 45% OPC and the one- sided 95% credible upper bound of the safety rate is 
below the 25% OPC.  The use of one -sided testing is consistent with the  original protocol.  
Supportive Analyses: The powers w ill be 90% to rule out a 46% OPC (efficacy) margin (lower 
bound) and 90% to rule out a 15% OPC (safety) margin (upper bound) using two- sided tests.  
The trial will be considered successful if the two -sided 95% credible lower bound of the efficacy 
rate exceeds the 46% OPC and the two -sided 95% credible upper bound of the safety rate is 
below the 15% OPC.  The use of two- sided testing is consistent with the PIPELINE PMA and 
FDA guidance.  
Study success is de fined as achieving statistical significance for the primary OPCs.  
 
 
 
 CONFIDENTIAL  Page 12 of 21  
  Thus , both one -sided and two- sided credible intervals will be computed for the primary (one -
sided) and supportive (two- sided) analyses.  However, since the success standards are higher for 
both safety and efficacy for the supportive analyses  than for the primary analyses , credible 
interval claims in support of labeling will be sought based on the more restrictive supportive 
analyses which are nested within the alternative hypotheses .   
5 ANALYS IS POPULATIONS  
The statistical analysis will use three populations:  
 
1) The Intent to Treat (ITT) population will consist of all enrolled subjects who had an 
introduction of the FRED Implant System into the bloodstream . The ITT population will be used 
for all effectiveness analyses to test the efficacy hypothesis  for both OPC sets .  
 
2) The Safety Population will consist of all subjects in whom the investigational device was 
implanted as well as deaths due to technical failures during the index procedure. The Safety 
Population will be used to test the safety hypothesis  for both OPC sets .  
 
3) The Per Protocol Population will consist of all subjects in the ITT Population for whom there 
were no major protocol deviations.  All protocol deviations will be assessed by the Clinical 
Events Committee.  
 
The primary and secondary effectiveness endpoints will also be evaluated for the Per Protocol 
Population.  
 
6 GENERAL CONSIDERATIONS  
6.1 BASELINE  
Unless otherwise specified, baseline is defined as the last non- missing measurement taken prior 
to or on the study start date/time.  
6.2 CRITERIA FOR SUCCESS  FOR PRIMARY ENDPOINT ANALYSES  
Primary efficacy and safety will be assessed by employing a Bayesian approach. Bayesian 
statistics are a principl ed approach for learning from evidence as it accumulates (FDA 2010, 
FDA guidance for industry and FDA staff guidance for the use of Bayesian statistics in medical 
device clinical trials, FDA CDRH CBER, February 5, 2010).  
For the primary endpoints, t he cri terion for success is based on the posterior probability of the 
alternative hypothesis. The FRED device will be declared  efficacious  if the one -sided 95% lower 
 
 
 
 CONFIDENTIAL  Page 13 of 21  
  credible limit is at least 45% . The performance goal was obtained from a formal comprehensive 
literature review and meta- analysis of results from studies of flow diverters to treat patients 
matched to the FRED study subjects during the first year after treatment. Similarly, the FRED  
will be declared safe if the one -sided 95% upper credible limit is at most 25% . The performance 
goal used in the P100018 SSED of the Pipeline PUFS study was 20%.  
However, the definition used in the PUFS study did not include all death and major stroke within 
30 days, only death of neurologic cause and major ipsilateral strokes, and it was only evaluated 
through 180 days, not 12 months. For this reason, the performance goal utilized here is slightly  
higher. The primary safety endpoint in this study has not been used or reported as such  
previously, so the magnitude of the effect of this change is unknown. For the purposes of the  
current study a conservative 5% adjustment is used, resulting in a 25% performance goal (20%  
from above + 5% conservative adjustment).  
6.3 ANALYSIS SOFTWARE  
Statistical analyses will be performed using  SAS version 9.3 or above (SAS Institute, Cary, NC, 
USA), R version 3.2 or above (R Foundation for Statistical Computing, Vienna, Austria) or other 
widely accepted statistical software.  For Baye sian analyses of  the primary endpoints, posterior 
estimates of modeled parameters  will be  reported along with the relevant one- sided and two -
sided 95% credible intervals . 
Descriptive s tatistics for continuous variables will include the mean, standard deviation, median, 
quartiles, and sample size for each treatment group. Categorical variables will be summarized 
using frequency distributions including counts and percentages. Proportions will be calculated 
using known non- missing values.   
6.4 DISPOSITION OF SUBJECTS AND WITHDRAW ALS 
All subjects who provide written informed consent will be accounted for. The frequency and 
percent age of subjects who complete  each scheduled assessment will be summarized in a tabular 
format  including  details on st udy exits with reason for exit.   
6.5 PROTOCOL DEVIATIONS  
Major protocol deviations  will be summarized. This summary will include the number and 
percent of subjects with each major deviation type.  A major protocol deviation is defined as  a 
subject  enrolled and treated, but who subsequently does  not meet inclusion criteria or does  meet 
exclusion criteria  or have other deviations determined to impact the primary efficacy or safety 
endpoints  analyses  for this trial.  Additionally, a ll protocol deviati ons, major and minor, will be 
 
 
 
 CONFIDENTIAL  Page 14 of 21  
  summarized.   This summary will include the number and percent of subjects with each protocol 
deviation) and reason within each time interval.  
6.6 MISSING DATA IMPUTATIONS  
No safety data will be imputed whereas efficacy data may b e imputed based on subject -specific 
situations.  Regarding efficacy, for a ny subjects missing 12- month clinical, neurological and 
angiographic evaluation s, the most likely 12 -month efficacy outcomes  at the subject -level  will be 
imputed .  For this purpose, all available 12 -month data will be included.  Additionally, for 
subjects not reporting 12 -month occlusion data, results may  be imputed from 6- month occlusion 
data along with available pre -treatment data.  Safety data will not be imputed; 12 -month contact 
will be sought to confirm stroke and survival status to confirm safety success. Subjects with no 
follow -up data will not be imputed for analysis of the primary effectiveness endpoint but 
alternative source- document verified data will be considered in judgi ng 12 -month efficacy.   
In the event such imputations for the subjects with missing 12- month data  cannot be made , then 
the other subjects with  completed 6 -month and 12- month safety and efficacy outcomes will be 
used to compute the respective probabilities of 12 -month efficacy  outcomes  conditional on 6 
month outcome s for the respective ITT, Safety, and PP populations.   
6.7 MULTIPLE COMPARISONS AND MULTIPLICITY  
The study requires both the primary safety and primary efficacy  endpoints be met  to declare 
study success, and therefore  no multiplicity adjustment is required  for declaring study success .   
Also, given that the success standards are higher for both safety and efficacy for the supportive 
analyses than for the primary analyses, as long  as statistical significance is achieved for the 
primary analyses, there is no statistical penalty required to make conclusions based on the more 
restrictive supportive analyses which are nested within the alternative hypotheses being tested .  
7 ENDPOINT  ANALYSES  
7.1 PRIMARY EFFICACY VARIABLE  
The primary eff icacy  endpoint is the percent of subjects in the ITT population with complete 
occlusion ( defined as Raymond c lass I) without clinically s ignificant stenosis (defined as â‰¥ 50% 
stenosis) of the parent artery at the target IA based on core lab evaluations at the 12- month 
follow -up angiography and  in whom an alternative treatment of the target IA had not been 
performed  post -FRED placement . An alternative treatment is defined as re -treatment of the 
target aneurysm with an alternative treatment modality including open repair, endovascular 
 
 
 
 CONFIDENTIAL  Page 15 of 21  
  placement of an additional stent or treatment of In -stent Stenosis observed at the 180- day or 12 
month f ollow -up time -points or at an unscheduled study follow up visit . 
The primary eff icacy  hypotheses are:  
ğ»ğ»E0: ğœ‹ğœ‹ğ¸ğ¸â‰¤0.45 
ğ»ğ»E1: ğœ‹ğœ‹ğ¸ğ¸>0.45 
The null hypothesis ( ğ»ğ»ğ¸ğ¸0) for this endpoint states that the true proportion of subjects treated with 
the FRED  Device who  achieve complete occlusion (Raymond class I) without clinically 
significant (â‰¥ 50%) stenosis of the parent artery 12 months post -treatment and without any 
subsequent alternative treatment is no higher than 45%.  The alternative hypothesis the FRED  
trial a ims to demonstrate is that the true proportion of subjects who achieve effectiveness  success 
at 12 months is greater than 45%.   
Using the prior  
ğœ‹ğœ‹ğ¸ğ¸âˆ¼ğµğµğµğµğµğµğµğµ (1,1)  
the posterior distribution for the primary efficacy  endpoint rate will be  
ğœ‹ğœ‹ğ¸ğ¸ | ğ¸ğ¸,ğ‘›ğ‘› ~ ğµğµğµğµğµğµğµğµ (1+ğ¸ğ¸,1+ğ‘›ğ‘› â€“ ğ¸ğ¸) 
where ğ‘›ğ‘› is the number of evaluable subjects and ğ¸ğ¸ is the number of subjects who meet the 
efficacy endpoint.  The point estimate of the posterior distribution of the primary efficacy  
endpoint will be presented with its lower 95% credible bound, as well as the posterior probability 
of the alternative hypothesis ğ»ğ» ğ¸ğ¸1.  If the posterior probability exceeds 0.95, the primary efficacy 
endpoint will have been met.  
7.2 PRIMARY SAFETY ENDPOINT  
The studyâ€™s primary safety endpoi nt is the proportion of subjects  in the Safety  Population who 
experience either major stroke or death within 30 days, or major ipsilateral stroke or neurological 
death 31 days through 12 months  post procedure .  CEC -adjudicated  data will be used for this 
analysis.  
The primary safety hypotheses are:  
ğ»ğ»S0: ğœ‹ğœ‹ğ‘†ğ‘†â‰¥0.25 
ğ»ğ»S1: ğœ‹ğœ‹ğ‘†ğ‘†<0.25 
 
 
 
 CONFIDENTIAL  Page 16 of 21  
  The null hypothesis ( ğ»ğ»ğ‘†ğ‘†0) for this endpoint states that the true proportion of subjects treated with 
the FRED  Device who experience neurologic  death  or major ipsilateral stroke  one-year post -
treatment is equal to or  higher than 25%.  The alternative hypothesis the FRED  trial aims to 
demonstrate is that the true proportion of subjects treated with the FRED  Device who experience 
neurologic death or major ipsilateral stroke one -year post -treatment is actually lower than 25 %.  
Using the noninformative  prior  
ğœ‹ğœ‹ğ‘†ğ‘†âˆ¼ğµğµğµğµğµğµğµğµ (1,1)  
the posterior distribution for the primary safety endpoint event rate will be  
ğœ‹ğœ‹ğ‘ ğ‘  | ğ‘†ğ‘†,ğ‘›ğ‘› ~ ğµğµğµğµğµğµğµğµ (1+ğ‘†ğ‘†,1+ğ‘›ğ‘› â€“ ğ‘†ğ‘†) 
where ğ‘›ğ‘› is the number of evaluable subjects and ğ‘†ğ‘† is the number of subjects who meet the safety  
endpoint.  The point estimate of the posterior distribution of the primary safety endpoint will be 
presented with its lower 95% credible bound, as well as the posterior probability of the 
alternative hypothesis  ğ»ğ»ğ‘†ğ‘†1. If the posterior probability exceeds 0.95, the primary safety endpoint 
will have been met   
The supportive  analysis (second OPC set) will be conducted for both primary efficacy and 
primary safety using  more restrictive  performance goals identified from a revised set of literature 
analysis  and presented to FDA on 16 February 20 17.  T he format of this analysis will be a 
Bayesian design identical in form to the above exc ept that the performance goals will be 0.46 for 
efficacy and 0.15 for safety .  Details of the resulting analyses an d associated power are as below, 
from which it can be seen that the study is sufficiently powered at the final enrolled and treated 
count of 140.   
 
 
7.3 MISSING DATA ANALYSES   Efficacy  Safety  
 Original Revised  Original  Revised  
Significance level,  alpha  0.05 0.025  0.05 0.025  
1 or 2 -sided test  1 1 1 1 
Null: OPC, p 0 0.45 0.46 0.25 0.15 
Alternative: FRED, p A 0.58 0.60 0.15 0.06 
Power (%)  90 90 90 92 
N 140 140 140 140 
 
 
 
 CONFIDENTIAL  Page 17 of 21  
  Subjects are expected to comply with the follow -up schedule.  E fforts to prevent missing data 
include, but are not limited to, a reminder for the scheduled 30- day, 180 days and 12 -month 
follow -up, obtaining additional phone numbers or contact information f or all subjects at the time 
of the procedure along with requesting permission to contact the subjectâ€™s family members or 
care-givers, and collecting only necessary data to reduce the burden to subjects and investigators. 
In-depth site training and regular monitoring will also help to minimize missing data , and 
collaborating with the Investigators to ensure the subjects are committed to complying with all 
scheduled follow -up visits . 
Subject compliance with required follow up will be tabulated and reported as  proportions. 
Subjects who withdraw from the study will be tabulated with the reasons for the withdrawal .  
For subjects not reporting 12- month occlusion data, the 180- day efficacy outcomes will be used 
to impute 12- month efficacy results . A conditional analysis will be performed to determine the 
probability of 12- month efficacy (success, failure) based on 180- day efficacy (success, failure).  
Tipping point  analyses will be performed to include data on subjects without the primary safety 
or efficacy endpoints (missing data or subjects lost to follow -up).  
7.4 CENTER HETEROGENEITY  
To assess consistency of treatment effect size across study centers, any study center with less 
than 5 subjects will be pooled with other such study centers prior to c arrying out this assessment.  
A number  of measures have been taken to assure center heterogeneity : 
â€¢ the study sites were monitored for protocol compliance,  
â€¢ the same data gathering instrument and method were used in every site.    
â€¢ investigators are selected f or their experience and ability in performing interventional 
neurovascular procedures  
â€¢ investigational sites are required to follow the same detailed protocol with explicit 
inclusion and exclusion criteria   
â€¢ the primary safety and eff icacy  endpoints of this study are objective events determined 
by a central CEC and independent angiographic core laboratory.  
An analysis of comparability across study sites will be carried out to determine the similarity of 
study sites with respect to important demographic and ot her variables, either known or suspected 
to have an influence on the outcome variables.   
Individual data, for individual ğ‘˜ğ‘˜  will be assumed to follow a Bernoulli distribution:  
ğ‘Œğ‘Œ[ğ‘˜ğ‘˜]~ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğµğµğ‘‘ğ‘‘ğ‘›ğ‘›(ğ‘ğ‘[ğ‘ğ‘ğµğµğ‘›ğ‘›ğµğµğµğµğ‘‘ğ‘‘ [ğ‘˜ğ‘˜]]) 
 
 
 
 CONFIDENTIAL  Page 18 of 21  
  where center is an index variable that indicates the center that the individual ğ‘˜ğ‘˜  was recruited in. 
Statistical testing will be performed using Pearsonâ€™s chi- square test.  
7.5 SUBGROUP ANALYSIS  
Subgroups for secondary analysis of primary endpoints (safety and efficacy) include:  
â€¢ Location (anterior, posterior)  
â€¢ Age ( <60, 60 -69, â‰¥70)  
â€¢ Gender: results will be stratified by gender  
â€¢ Anatomic location (zone 1, 2 and 3)  
â€¢ Vascular risk factor: Hypertension (Yes, No)  
â€¢ Vascular risk factor: Hyperlipidemia (Yes, No)  
â€¢ Vascular risk factor: Tobacco Use (Yes, No)  
The success percents for primary endpoint s will be presented descriptively within each subgroup 
and global tests of significance on the endpoint s will be performed to check the heterogeneity of 
differences in the primary endpoint  success percent s for safety and efficacy  across all subgroups.   
The purpose of this analysis is not to formally assess success  within each subgroup, but simply to 
assess consistency of results across the various subgroups.  
7.6 SECONDARY ENDPOINT  VARIABLES  
A Bayesian analysis will be employed in assessment of s econdary endpoint s.  
For all dichotomous secondary endpoints, the model employed to summarize the rate ( ğœ‹ğœ‹) of 
secondary endpoint will be similar to the model employed for the analysis of the primary 
endpoints. More specifically, under the prior for the rate  
  
ğœ‹ğœ‹âˆ¼ğµğµğµğµğµğµğµğµ (1,1)  
 
the posterior distribution for the secondary  endpoint event rate will be  
ğœ‹ğœ‹ | ğ‘Œğ‘Œ,ğ‘›ğ‘› ~ ğµğµğµğµğµğµğµğµ (1+ğ‘Œğ‘Œ,1+ğ‘›ğ‘› â€“ ğ‘Œğ‘Œ) 
where ğ‘›ğ‘› is the number of evaluable subjects and ğ‘Œğ‘Œ is the number of subjects with events . The 
rate of the endpoint with a 95% c redible  interval will be  reported; both one -tailed and two -tailed 
intervals will be computed to be consistent with the two OPC sets .  In addition to the results 
based on the model, raw counts and proportions will be reported.  
 
 
 
 CONFIDENTIAL  Page 19 of 21  
  For all continuous secondary endpoints, the Bayesian model employed to summarize the mean 
outcome ( ğœ‡ğœ‡) and standard deviance ( ğœğœ) of secondary endpoint will use a conjugate analysis 
where the point and interval estimates are numerically the same as the sample mean and sample 
standard deviation. More specifically, the prior for the mean and variance will be  
 
ğ‘ğ‘(ğœ‡ğœ‡,ğœğœ2)âˆğœğœâˆ’2  
 
the posterior distribution for the secondary  endpoint mean  (ğœ‡ğœ‡) and variance ( ğœğœ2) will be  
ğœ‡ğœ‡ | ğ‘Œğ‘Œ1,ğ‘Œğ‘Œ2,â€¦,ğ‘Œğ‘Œğ‘›ğ‘›,ğœğœ2,ğ‘›ğ‘› ~ ğ‘ğ‘ğ‘ğ‘ğ‘‘ğ‘‘ğ‘ğ‘ğµğµğ‘ğ‘ï¿½ğ‘Œğ‘Œï¿½ğ‘›ğ‘›,ğœğœ2
ğ‘›ğ‘›ï¿½ 
(ğ‘›ğ‘›âˆ’1)ğ‘†ğ‘†2
ğœğœ2| ğ‘Œğ‘Œ1,ğ‘Œğ‘Œ2,â€¦,ğ‘Œğ‘Œğ‘›ğ‘›,ğ‘›ğ‘›âˆ¼ğœ’ğœ’2(ğ‘›ğ‘›âˆ’1) 
where ğ‘›ğ‘› is the number of evaluable subjects and ğ‘Œğ‘Œ1,ğ‘Œğ‘Œ2,â€¦,ğ‘Œğ‘Œğ‘›ğ‘› are the data collected on the ğ‘›ğ‘›  
subjects and ğ‘†ğ‘†2 is the sample variance.  The mean and standard deviation rate of the posterior 
distribution of the mean and variance of the secondary endpoint with an equitailed 95% c redible  
interval will be  reported.  
7.6.1  PROTOCOL DEFINED SECONDARY ENDPOINT VARIABLES  
Seco ndary endpoints as defined in S ection 4.4 will be  summarized and reported .  No formal 
hypothesis testing for success is planned for these endpoints. 
7.7 MEDICAL HISTORY  
Medical history will be summarized.  For each condition, the number and percent of subjects  
with the condition will be presented.  In addition, previous aneurysm treatments and current 
status of aneurysm will be summarized.  
7.8 LABS 
Laboratory values obtained at baseline will be summarized . The  number of subjects who 
completed each lab and the number and percent of subjects with clinically abnormal  values for 
each lab  will be summarized .  This summary will be purely descriptive in nature.  A listing of 
subject lab values will be compiled and included in an appendix to the CSR. 
7.9 PROCEDURE  
 
 
 
 CONFIDENTIAL  Page 20 of 21  
  FRED  device utilization will be presented , including number of devices and percent of subjects 
within each category . Other procedural information including procedural technique and 
medications (anti- coagulants and anti -platelets) utilized intra -procedurally will be similarly 
summarized.  
8 ADVERSE EVENTS  
Adverse events will be adjudicated by the CEC in accordance with the CEC Manual of 
Procedures (MOP) presented accordingly . The results of CEC adjudication will serve as the basis 
for the summary tabulations of all adver se events in this trial.   Analyses and displays will be 
based on CEC findings.  
8.1 ALL ADVERSE EVENTS  
Summaries of incidence rates,  seriousness and relationship to the investigational device of 
individual AEs and SAEs will be presented . Because a subject  may experience more than one 
AE, summaries will provide both the number of subjects and the number of events. Percentages 
provided will be the percent of subjects experiencing one or more adverse events.  
AE summaries will be conducted using the CEC adjudicate d assessments.   AE summaries will be 
presented for serious and non- serious adverse device effect s, serious and non- serious adverse 
events to be categorized into neurologic vs non -neurologic . 
Additionally, separate CEC and site l isting s will be generated to  include the subject number, AE 
number, days since FRED  Device implant , whether or not the AE is classified as an SAE, and 
the relationship of the AE to the investigational device or procedure  as determined by the CEC .   
8.2 SERIOUS ADVERSE EVENTS  
Summaries of incidence rates and relationship to the investigational device of individual SAEs 
will be included in the CSR . Summaries will provide both the number of subjects and the 
number of events.  Percentages provided will be the percent of subjects e xperiencing one or more 
serious adverse events.  SAE summaries will be conducted using the CEC adjudicated 
assessments.  A data listing of SAEs will also be provided, displaying details of the event(s) 
captured in the database.  
8.3 DEATHS  
For any deaths  occurr ing during the course of the FRED  study , a full narrative will be provided 
and relevant inform ation will be supplied . All deaths will be summarized separately including 
cause, device, and procedure relatedness per CEC determination.  
 
 
 
 CONFIDENTIAL  Page 21 of 21  
  9 OTHER PLANNED ANALYSES  
9.1 CONCOMITANT MEDICATIONS  
Medications  are to be reported in the concomitant medications log.  A listing of all medications 
used will be created  and included as an appendix to the CSR. Anti -coagulants, and anti -platelet 
medication usage will b e tabulated.  
9.2 DEVICE OBSERVATIONS  
A description of any  device observations will be provided in the CSR . The summary will include 
the number of observations and the percent age. Additionally, all device observations will be 
provided in a  listing for further detail.  
9.3 ADDITIONAL INTERVENTIONS AND REINTERVENTIONS  
A summary of retreatment  the target aneurysm through 12 -month follow up will be prepared. In 
addition, a  Kaplan -Meier curve showing the time to retreatment  will be included in the CSR.  
Retreatment  will be timed  as soon as a subject undergoes an additional (at time of initial 
intervention) or subsequent intervention of the treated aneurysm.  
9.4 STATISTICAL ANALYSIS PLAN REVISIONS  
The SAP will be approved prior to analysis of outcomes from the database.   The final rep ort may 
contain additional tables, footnotes or statistical tests if w arranted by the data obtained.  These 
analyses will be clearly described as post hoc analyses . 
 